Analysis of the Mechanism for the Development of Allergic Skin Inflammation and the Application for Its Treatment: Overview of the Pathophysiology of Atopic Dermatitis

by Tadashi Terui
Published 2009-01-01

Disulfide-linked dimerization of the FcRγ chain is required for positive and negative regulation of mast cell activation via FcεRI

by Satoshi Nunomura, Chisei Ra, Tadashi Terui, Yoshimichi Okayama
Published 2017-09-01

A Novel NCSTN Gene Mutation in a Japanese Family with Hidradenitis Suppurativa

by Nobuyuki Nishimori, Koremasa Hayama, Kumiko Kimura, Hideki Fujita, Kyoko Fujiwara, Tadashi Terui
Published 2020-10-01

Serum level of hemokinin-1 is significantly lower in patients with chronic spontaneous urticaria than in healthy subjects

by Nobuyuki Nishimori, Shota Toyoshima, Tomomi Sasaki-Sakamoto, Koremasa Hayama, Tadashi Terui, Yoshimichi Okayama
Published 2021-10-01

Aggressive CD4–CD8–CD45RA+CCR10– Primary Cutaneous Peripheral T-cell Lymphoma, Not Otherwise Specified: A Case Report

by Natsumi Ikumi, Hideki Fujita, Tadashi Terui, Hiromichi Takahashi, Katsuhiro Miura, Yoshihiro Hatta, Masami Takei
Published 2019-09-01

Activation of LXRs using the synthetic agonist GW3965 represses the production of pro-inflammatory cytokines by murine mast cells

by Satoshi Nunomura, Yoshimichi Okayama, Kenji Matsumoto, Noriko Hashimoto, Kaori Endo-Umeda, Tadashi Terui, Makoto Makishima, Chisei Ra
Published 2015-09-01

Spitz nevus with unusual dermoscopic figures in an adult female

by Hironori Kawana, Hideki Fujita, Daisuke Fujisawa, Madoka Ishii, Miwa Murata, Ayano Kurumatani, Koremasa Hayama, Masaru Tanaka, Tadashi Terui
Published 2020-06-01

Differentiation between control subjects and patients with chronic spontaneous urticaria based on the ability of anti-IgE autoantibodies (AAbs) to induce FcεRI crosslinking, as com...

by Satoshi Izaki, Shota Toyoshima, Takahiro Endo, Kazuko Kanegae, Satoshi Nunomura, Jun-ichi Kashiwakura, Tomomi Sasaki-Sakamoto, Ryosuke Nakamura, Haruyo Akiyama, Chisei Ra, Koremasa Hayama, Tadashi Terui, Yoshimichi Okayama
Published 2019-07-01

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

by April Armstrong, Carle Paul, Luis Puig, Wolf Henning Boehncke, Michael Freeman, Hideshi Torii, Kim Papp, Christopher E. M. Griffiths, Andrew Blauvelt, Kristian Reich, Melinda Gooderham, Tadashi Terui, Lisa Renda, Noah Agada, Wen Xu, Gaia Gallo, Mark G. Lebwohl
Published 2019-11-01